213 related articles for article (PubMed ID: 24261756)
1. Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I).
Yamanaka H; Sugiyama N; Inoue E; Taniguchi A; Momohara S
Mod Rheumatol; 2014 Jan; 24(1):33-40. PubMed ID: 24261756
[TBL] [Abstract][Full Text] [Related]
2. Update on the prevalence and incidence of rheumatoid arthritis in Korea and an analysis of medical care and drug utilization.
Won S; Cho SK; Kim D; Han M; Lee J; Jang EJ; Sung YK; Bae SC
Rheumatol Int; 2018 Apr; 38(4):649-656. PubMed ID: 29302803
[TBL] [Abstract][Full Text] [Related]
3. Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA.
Shidara K; Hoshi D; Inoue E; Yamada T; Nakajima A; Taniguchi A; Hara M; Momohara S; Kamatani N; Yamanaka H
Mod Rheumatol; 2010 Jun; 20(3):280-6. PubMed ID: 20217173
[TBL] [Abstract][Full Text] [Related]
4. Wide difference in biologics usage and expenditure for the treatment of patients with rheumatoid arthritis in each prefecture in Japan analyzed using "National Database of Health Insurance Claims and Specific Health Checkups of Japan".
Kamata Y; Minota S
Rheumatol Int; 2018 Apr; 38(4):663-668. PubMed ID: 29204683
[TBL] [Abstract][Full Text] [Related]
5. Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan.
Yamanaka H; Inoue E; Singh G; Tanaka E; Nakajima A; Taniguchi A; Hara M; Tomatsu T; Kamatani N
Mod Rheumatol; 2007; 17(4):283-9. PubMed ID: 17694260
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology and Treatment of New-Onset and Established Rheumatoid Arthritis in an Insured US Population.
Crane MM; Juneja M; Allen J; Kurrasch RH; Chu ME; Quattrocchi E; Manson SC; Chang DJ
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1646-55. PubMed ID: 26097059
[TBL] [Abstract][Full Text] [Related]
7. Prescription patterns and trends in anti-rheumatic drug use based on a large-scale claims database in Japan.
Katada H; Yukawa N; Urushihara H; Tanaka S; Mimori T; Kawakami K
Clin Rheumatol; 2015 May; 34(5):949-56. PubMed ID: 24420724
[TBL] [Abstract][Full Text] [Related]
8. Recent trends in use of nonbiologic DMARDs and evaluation of their continuation rates in single and dual combination therapies in rheumatoid arthritis patients in Japan.
Ogasawara M; Kageyama M; Kusaoi M; Onuma S; Kon T; Sekiya F; Sugimoto K; Matsudaira R; Matsushita M; Tada K; Kempe K; Yamaji K; Tamura N; Takasaki Y
Mod Rheumatol; 2012 Nov; 22(6):831-6. PubMed ID: 22350576
[TBL] [Abstract][Full Text] [Related]
9. [Medical treatment of rheumatoid arthritis in 2014 : Current data from the German Collaborative Arthritis Centers].
Albrecht K; Huscher D; Eidner T; Kleinert S; Späthling-Mestekemper S; Bischoff S; Zink A
Z Rheumatol; 2017 Feb; 76(1):50-57. PubMed ID: 27379740
[TBL] [Abstract][Full Text] [Related]
10. Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012.
Sato E; Tanaka E; Ochiai M; Shimizu Y; Kobayashi A; Shidara K; Hoshi D; Sugimoto N; Inoue E; Seto Y; Nakajima A; Taniguchi A; Momohara S; Yamanaka H
Mod Rheumatol; 2015 May; 25(3):350-7. PubMed ID: 25619283
[TBL] [Abstract][Full Text] [Related]
11. Standard treatment in daily clinical practice for early rheumatoid arthritis improved disease activity from 2001 to 2006.
Nakajima A; Inoue E; Shidara K; Hoshi D; Sato E; Seto Y; Tanaka E; Taniguchi A; Momohara S; Yamanaka H
Mod Rheumatol; 2011 Dec; 21(6):594-7. PubMed ID: 21516373
[TBL] [Abstract][Full Text] [Related]
12. Analysis of direct medical and nonmedical costs for care of rheumatoid arthritis patients using the large cohort database, IORRA.
Tanaka E; Hoshi D; Igarashi A; Inoue E; Shidara K; Sugimoto N; Sato E; Seto Y; Nakajima A; Momohara S; Taniguchi A; Tsutani K; Yamanaka H
Mod Rheumatol; 2013 Jul; 23(4):742-51. PubMed ID: 22878927
[TBL] [Abstract][Full Text] [Related]
13. Impact of physicians' adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial.
Kuusalo L; Puolakka K; Kautiainen H; Blåfield H; Eklund KK; Ilva K; Kaipiainen-Seppänen O; Karjalainen A; Korpela M; Valleala H; Leirisalo-Repo M; Rantalaiho V;
Scand J Rheumatol; 2015; 44(6):449-55. PubMed ID: 26324784
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan.
Nakajima A; Sakai R; Inoue E; Harigai M
Int J Rheum Dis; 2020 Dec; 23(12):1676-1684. PubMed ID: 33016574
[TBL] [Abstract][Full Text] [Related]
15. Influence of methotrexate dose on its efficacy and safety in rheumatoid arthritis patients: evidence based on the variety of prescribing approaches among practicing Japanese rheumatologists in a single institute-based large observational cohort (IORRA).
Yamanaka H; Inoue E; Tanaka E; Nakajima A; Taniguchi A; Terai C; Hara M; Tomatsu T; Kamatani N
Mod Rheumatol; 2007; 17(2):98-105. PubMed ID: 17437163
[TBL] [Abstract][Full Text] [Related]
16. Medical care costs of patients with rheumatoid arthritis during the prebiologics period in Japan: a large prospective observational cohort study.
Tanaka E; Inoue E; Mannalithara A; Bennett M; Kamitsuji S; Taniguchi A; Momohara S; Hara M; Singh G; Yamanaka H
Mod Rheumatol; 2010 Feb; 20(1):46-53. PubMed ID: 19821162
[TBL] [Abstract][Full Text] [Related]
17. Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate.
Kobayakawa T; Kojima T; Takahashi N; Hayashi M; Yabe Y; Kaneko A; Shioura T; Saito K; Hirano Y; Kanayama Y; Miyake H; Asai N; Funahashi K; Hirabara S; Hanabayashi M; Asai S; Ishiguro N
Mod Rheumatol; 2015 Mar; 25(2):251-6. PubMed ID: 25211402
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with frailty in Japanese patients with rheumatoid arthritis: results from the Institute of Rheumatology Rheumatoid Arthritis cohort study.
Furuya T; Oh K; Ikari K; Inoue E; Tanaka E; Yamanaka H; Harigai M
Clin Rheumatol; 2022 Feb; 41(2):405-410. PubMed ID: 34586516
[TBL] [Abstract][Full Text] [Related]
19. Current treatments of rheumatoid arthritis: from the 'NinJa' registry.
Saeki Y; Matsui T; Saisho K; Tohma S
Expert Rev Clin Immunol; 2012 Jul; 8(5):455-65. PubMed ID: 22882220
[TBL] [Abstract][Full Text] [Related]
20. Potential impact of observational cohort studies in Japan on rheumatoid arthritis research and practice.
Yamanaka H; Tohma S
Mod Rheumatol; 2006; 16(2):75-6. PubMed ID: 16633925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
